Cost-Effectiveness Analysis of Psoriasis Treatment Modalities in Malaysia

Document Type: Original Article

Authors

1 Department of Community Health, Faculty of Medicine, Universiti Kebangsaan Malaysia, Selangor, Malaysia

2 Faculty of Business and Management, Universiti Teknologi MARA Selangor, Selangor, Malaysia

3 Department of Community Health, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

4 Medical Department, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

Abstract

Background
There is limited evidence detailing the cost-effectiveness of psoriasis treatments in the Asian region. Therefore, this study is aimed to evaluate the cost-effectiveness of 3 psoriasis treatments tailored for moderate to severe psoriasis, namely topical and phototherapy (TP), topical and systemic (TS), and topical and biologic (TB) regimens, respectively.


Methods
This has been achieved by the participation of a prospective cohort involving a total of 90 moderate to severe psoriasis patients, which has been conducted at 5 public hospitals in Malaysia. The main outcome measures have been evaluated via cost and effectiveness psoriasis area severity index (PASI)-75 and/or body surface area (BSA)

Keywords

Main Subjects


  1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70 (3):512-516. doi:10.1016/j.jaad.2013.11.013
  2. Springate DA, Parisi R, Kontopantelis E, Reeves D, Griffiths CEM, Ashcroft DM. Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol. 2017;176 (3):650-658. doi:10.1111/bjd.15021
  3. Ding X, Wang T, Shen Y, et al. Prevalence of psoriasis in China: a population-based study in six cities. Eur J Dermatol. 2012;22 (5):663-667. doi:10.1684/ejd.2012.1802
  4. Mohd Affandi A, Ngah Saaya N, Johar A, Muneer A, Hamid A. Annual Report of the Malaysian Psoriasis Registry 2007-2015. Vol 13. Kuala Lumpur; 2017.
  5. Thorleifsdottir R, Sigurdardottir S, Sigurgeirsson B, et al. Patient-reported outcomes and clinical response in patients with moderate-to-severe plaque psoriasis treated with tonsillectomy: a randomized controlled trial. Acta Derm Venereol. 2017:97(3):340-345. doi:10.2340/00015555-2562
  6. Ministry of Health. Management of Psoriasis Vulgaris. Kuala Lumpur; 2013.
  7. Carrascosa JM, Bonanad C, Dauden E, Botella R, Olveira-Martín A. Psoriasis and nonalcoholic fatty liver disease on behalf of the systemic inflammation in psoriasis working group. Actas Dermosifiliogr. 2017;108 (6):506-514.
  8. Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol. 2013;27(1):e30-e41. doi:10.1111/j.1468-3083.2012.04450.x
  9. Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77(2):287-292.e4. doi:10.1016/j.jaad.2017.03.037
  10. Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS One. 2017;12(7):e0181039. doi:10.1371/journal.pone.0181039
  11. Vañó-Galván S, Gárate MT, Fleta-Asín B, et al. Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis. Actas Dermosifiliogr. 2012;103(2):127-137. doi:10.1016/j.ad.2011.05.002
  12. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2009;60(4):643-659. doi:10.1016/j.jaad.2008.12.032
  13. Alfageme Roldán F, Bermejo Hernando A, Calvo González JL, Marqués Sánchez P. Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks. Rev Esp Salud Publica. 2016;90:E15.
  14. Czarnecka-Operacz M, Sadowska-Przytocka A. The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Postepy Dermatol Alergol. 2014;31 (6):392-400. doi:10.5114/pdia.2014.47121
  15. Oussedik E, Patel NU, Cash DR, Gupta AS, Feldman SR. Severe and acute complications of biologics in psoriasis. G Ital Dermatol Venereol. 2017;152(6):586-596. doi:10.23736/S0392-0488.17.05750-9
  16. Mansouri Y, Goldenberg G. Biologic safety in psoriasis: Review of long-term safety data. J Clin Aesthet Dermatol. 2015;8(2):30-42.
  17. Puig L, Julià A, Marsal S. The Pathogenesis and Genetics of Psoriasis. Actas Dermo-Sifiliográficas  (English Ed). 2014;105(6):535-545. doi:10.1016/j.adengl.2014.05.013
  18. Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ. Coste de la psoriasis y artritis psoriásica en cinco países de Europa: una revisión sistemática. Actas Dermosifiliogr. 2016;107 (7):577-590. doi:10.1016/j.ad.2016.04.018
  19. Spandonaro F, Ayala F, Berardesca E, et al. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs. 2014;28 (3):285-295. doi:10.1007/s40259-014-0084-3
  20. Korman NJ, Zhao Y, Pike J, Roberts J, Sullivan E. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity. Dermatol Online J. 2015;21 (10).
  21. Schmitt J, Küster D. Correlation between Dermatology Life Quality Index  (DLQI) scores and Work Limitations Questionnaire  (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis. Arch Dermatol Res. 2015;307 (5):451-453. doi:10.1007/s00403-015-1567-x
  22. Chan B, Hales B, Shear N, et al. Work-related lost productivity and its economic impact on Canadian patients with moderate to severe psoriasis. J Cutan Med Surg. 2009;13 (4):192-197.
  23. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199-205. doi:10.2147/PPA.S39887
  24. Li K, Armstrong AW. A review of health outcomes in patients with psoriasis. Dermatol Clin. 2012;30 (1):61-72. doi:10.1016/j.det.2011.08.012
  25. Zhang W, Islam N, Ma C, Anis AH. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics. 2015;33(4):327-340. doi:10.1007/s40273-014-0244-9
  26. Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013;54 (2):148-154. doi:10.1111/ajd.12014
  27. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303 (1):1-10. doi:10.1007/s00403-010-1080-1
  28. Ministry Of Health. Surat Pekeliling Bil. 1 Tahun 2014 - Garis Panduan Pelaksanaan Perintah Fi  (Perubatan)  (Kos Perkhidmatan). http://www.moh.gov.my/index.php/database_stores/store_view_page/31/257.  Published 2014. Accessed January 13, 2019.
  29. Sulong S, Ismail A, Azizam NA, Md Nor N, Ahmed Z. Economic burden and cost effectiveness analysis of psoriasis treatment modalities in Malaysian public hospitals: a study protocol. In: The European Proceedings of Social & Behavioural Sciences. Vol 5. Future Academy; 2016:243-250. doi:10.15405/epsbs.2016.11.02.23
  30. Küster D, Nast A, Gerdes S, et al. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting. Arch Dermatol Res. 2016;308 (4):249-261. doi:10.1007/s00403-016-1634-y
  31. D’Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, Toumi M. A cost effectiveness analysis of secukinumab 300 MG vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Value Heal. 2015;18:424.
  32. Knight C, Mauskopf J, Ekelund M, Singh A, Yang S, Boggs R. {C}ost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Heal Econ. 2012;13 (2):145-156.
  33. D’Souza LS, Payette MJ, Song M, Lim HW. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72 (4):589-598. doi:10.1016/j.jaad.2014.11.028
  34. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011;12 (13):2041-2054. doi:10.1517/14656566.2011.590475
  35. Sizto S, Bansback N, Feldman SRR, Willian MKK, Anis AHH. Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol. 2009;160 (6):1264-1272. doi:10.1111/j.1365-2133.2008.08962.x
  36. Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat. 2006;17 (1):29-37. doi:10.1080/09546630500504754
  37. Cabello Zurita C, Grau Pérez M, Hernández Fernández CP, et al. Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients. J Dermatolog Treat. 2017;28 (5):401-405. doi:10.1080/09546634.2016.1273469
  38. Knight C, Mauskopf J, Ekelund M, Singh A, Yang S, Boggs R. Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Heal Econ. 2012;13 (2):145-156. doi:10.1007/s10198-010-0293-8.
  39. Verma S, Dharmarajan S, Yang Y. PSS12 modeling the cost-effectiveness of ustekinumab for moderate to severe plaque psoriasis in US. Value Heal. 2010;13 (3):A147. doi:10.1016/S1098-3015(10)72715-7.
  40. Villacorta R, Hay JW, Messali A. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics. 2013;31 (9):823-839. doi:10.1007/s40273-013-0078-x
  41. Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14 (4):315-326. doi:10.1007/s40257-013-0030-z
  42. Salazar A, Aguirre A, Flores R. Cost-effectiveness analysis of ustekinumab for the treatment of adults with mild-to-moderate plaque psoriasis refractory to other biologic agents in Mexico. Value Heal. 2016;19 (3):A245. doi:10.1016/j.jval.2016.03.1046
  43. Armstrong AW, Betts KA, Signorovitch JE, et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Curr Med Res Opin. 2018;34 (7):1325-1333. doi:10.1080/03007995.2018.1457516
  44. de Argila D, Rodríguez-Nevado I, Chaves  a. Cost-Effectiveness Analysis Comparing Methotrexate With PUVA Therapy for Moderate—Severe Psoriasis in the Sanitary Area of Badajoz. Actas Dermo-Sifiliográficas  (English Ed). 2007;98 (1):35-41. doi:10.1016/S1578-2190 (07)70387-6
  45. Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag. 2008;4 (2):559-568.
  46. Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke W-H. Cost-effectiveness of psoriasis therapy with etanercept in Germany. J Dtsch Dermatol Ges. 2007;5 (9):762-768. doi:10.1111/j.1610-0387.2007.06489.x
  47. Johansson EC, Hartz S, Kiri SH, Kumar G, Svedbom A. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. J Med Econ. June 2018:1-11. doi:10.1080/13696998.2018.1474747
  48. Augustin M, McBride D, Gilloteau I, O’Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatology Venereol. 2018;32(12):2191-2199. doi:10.1111/jdv.15047
  49. Klijn SL, van den Reek JMPA, van de Wetering G, van der Kolk A, de Jong EMGJ, Kievit W. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE. Br J Dermatol. 2018;178 (5):1181-1189. doi:10.1111/bjd.16247
  50. Igarashi A, Kuwabara H, Fahrbach K, Schenkel B. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. J Dermatolog Treat. 2013;24 (5):351-355. doi:10.3109/09546634.2012.697111
  51. Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. Value Health. 2011;14 (5):652-656. doi:10.1016/j.jval.2011.01.006
  52. Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatology Venereol. 2010;24:17-22. doi:10.1111/j.1468-3083.2009.03563.x
  53. Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure psoriasis area and severity index  (PASI) in 5438 Swedish register patients. Am J Clin Dermatol. 2017;18 (4):583-590. doi:10.1007/s40257-017-0274-0
  54. Riveros BS, Ziegelmann PK, Correr CJ. Cost-effectiveness of biologic agents in the treatment of moderate-to-severe psoriasis: a Brazilian public health service perspective. Value Heal Reg Issues. 2014;5:65-72. doi:10.1016/j.vhri.2014.09.002
  55. Cohen S, Baron S, Archer C, British Association of Dermatologists and Royal College of General Practitioners. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol. 2012;37 Suppl 1:13-18. doi:10.1111/j.1365-2230.2012.04337.x
  56. Walsh JA, McFadden M, Woodcock J, et al. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69 (6):931-937. doi:10.1016/j.jaad.2013.07.040
  57. Mattei PLL, Corey KCC, Kimball ABB. Psoriasis Area Severity Index  (PASI) and the Dermatology Life Quality Index  (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28 (3):333-337. doi:10.1111/jdv.12106
  58. Blome C, Beikert FC, Rustenbach SJ, Augustin M. Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Arch Dermatol Res. 2013;305 (3):197-204. doi:10.1007/s00403-012-1309-2
  59. Herédi E, Rencz F, Balogh O, et al. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Heal Econ. 2014;15 (S1):111-119. doi:10.1007/s10198-014-0600-x
  60. Driessen RJB, Bisschops LA, Adang EMM, Evers AW, Van De Kerkhof PCM, De Jong EMGJ. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol. 2010;162 (6):1324-1329. doi:10.1111/j.1365-2133.2010.09693.x
  61. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146 (1):46-54. doi:10.1001/archdermatol.2009.319